Latest Posts › Corporate Governance

Share:

SEC in Discussion with Exchanges to Ease Public Company Regulations

The SEC is reportedly in discussions with Nasdaq and NYSE about ways to ease the burden of becoming—and remaining—a public company....more

SEC's Corp. Fin. Amends CDIs Related to Regulation 13D-G Reporting Rules

On July 11, the SEC’s Division of Corporation Finance amended 18 Compliance and Disclosure Interpretations relating to Regulation 13D-G, which pertains to beneficial ownership reporting rules.  These amendments bring the...more

NYSE Changes Rules on Initial Period Fees, How It Evaluates Listing Applications from Companies Outside North America

The New York Stock Exchange (Exchange) has recently adopted two rule changes, one to reduce fees for the initial period of a company’s listing on the Exchange and another to formally expand the universe of holders that will...more

Delaware Amends General Corporation Law to Stanch Company Exodus

On March 25, Delaware adopted significant amendments to §§ 144 and 220 of the Delaware General Corporation Law which aim to provide greater clarity and predictability to corporate fiduciaries in light of certain recent...more

SEC Updates CDIs on Schedules 13D and 13G Eligibility

The SEC published updated Compliance and Disclosure Interpretations on the filing of Schedules 13D and 13G/Shareholder Engagement....more

SEC Updates Guidance on Excluding Shareholder Proposals

The SEC rescinded Staff Legal Bulletin No. 14L and issued updated guidance on the exclusion of shareholder proposals under Rule 14a-8 and certain other aspects of Rule 14a-8....more

Key Takeaways for Life Sciences Companies Considering a 2025 IPO

The outlook for life sciences IPOs is showing renewed optimism heading into 2025, with market conditions becoming more constructive and regulatory environments potentially more favorable....more

Clinical Data FAQs: How to Approach Fundraising and Investor Relations

For publicly traded biotech companies, disclosing clinical trial data can be an exciting milestone as you build towards an exit or public offering—but disclosure is a double-edged sword....more

Clinical Data FAQs: How to Prepare for Disclosure

When it comes to disclosing clinical trial data in the biotechnology arena, in particular for public biotech companies, timing is everything. Disclosures are not just about when to reveal the information, but also what is...more

BlackRock’s 2025 U.S. Proxy Voting Guidelines

In December 2024, BlackRock released its updated U.S. proxy voting guidelines for benchmark policies. The changes will become effective as of January 2025. ...more

ISS Updates 2025 Benchmark Voting Policy and Executive Compensation FAQ

Institutional Shareholder Services updated its Benchmark proxy voting policies on December 17—with updated policies generally applying to shareholder meetings taking place on or after February 1. The updates for U.S....more

39 Results
 / 
View per page
Page: of 2

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide